AR882 50 mg, AR882 75 mg — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09 (month) in 2mo
ESTIMATED |
READOUT
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Phase 3 · Gout, Arthritis, Gouty |
Arthrosi Therapeutics | AR882 50 mg, AR882 75 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|